Last reviewed 2026-04-20 · How we verify

Perultid (NIPEROTIDINE)

Phase 2 active Small molecule

Perultid (generic name: NIPEROTIDINE) is a niperotidine drug. It is currently in Phase 2 development.

Perultid works by blocking histamine receptors in the stomach to reduce acid production.

Perultid (Niperotidine) is a small molecule drug that targets the histamine H2 receptor. It is a member of the niperotidine class and works by blocking the action of histamine at the H2 receptor, which is involved in stomach acid production. Perultid is not FDA-approved for any indications, and its commercial status, including patent status and generic availability, is unknown. As a result, its safety profile and key considerations are also not well established. Further research is needed to determine the potential benefits and risks of this drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NIPEROTIDINE
Drug class	niperotidine
Target	Histamine H2 receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your stomach lining has special receptors that respond to histamine, a chemical that tells your stomach to produce more acid. Perultid blocks these receptors, so your stomach doesn't get the signal to produce as much acid. This can help with conditions like ulcers or acid reflux.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Perultid CI brief — competitive landscape report
Perultid updates RSS · CI watch RSS

Frequently asked questions about Perultid

What is Perultid?

Perultid (NIPEROTIDINE) is a niperotidine drug.

How does Perultid work?

Perultid works by blocking histamine receptors in the stomach to reduce acid production.

What is the generic name of Perultid?

NIPEROTIDINE is the generic (nonproprietary) name of Perultid.

What drug class is Perultid in?

Perultid belongs to the niperotidine class. See all niperotidine drugs at /class/niperotidine.

What development phase is Perultid in?

Perultid is in Phase 2.

What does Perultid target?

Perultid targets Histamine H2 receptor and is a niperotidine.

Drug class: All niperotidine drugs
Target: All drugs targeting Histamine H2 receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing